biomarkers

**1290 CLINICAL RESPONSE TO THE MAGE-A3 IMMUNOTHERAPEUTIC IN METASTATIC MELANOMA PATIENTS IS ASSOCIATED WITH A SPECIFIC GENE PROFILE PRESENT PRIOR TO TREATMENT**

J. Lounaud1, B. Drijno2, S. Gaulis1, T. Helieupp3, P. Duport1, O. Grusselle1, A. Spatz4, W. Kruit5, F. Lehmann1, V.G. Brichard1

1Cancer Immunotherapeutics, GlaxoSmithKline, Rixensart/BELGIUM, 2Unit of Skin Cancer, University Hospital Nantes, Nantes/FRANCE, 3Machine Learning Group, University of Louvain, Louvain-La-Neuve/BELGIUM, 4Academic Unit of Clinical Oncology, Institut Gustave Roussy, Villejuif/FRA, 5Medical Oncology, Erasmus University Medical Centre, Rotterdam/NETHERLANDS

**Objectives:** Gene expressions profiling by microarrays are used to identify biomarkers predictive of the observed clinical activity of the MAGE-A3 Antigen-Specific Cancer Immunotherapeutic (ASCI) recorded in a Phase II study in metastatic melanoma (EORTC 16032-18031). Clinical activity to MAGE-A3 ASCI treatment in metastatic melanoma patients and a gene signature discriminating between clinical benefit and non clinical benefit patients were previously demonstrated (ASCO 2008). The predictive signature improved significantly the median time to treatment failure (2.3 months in the GS (-) and 10.3 months in the GS (+) population. Here we report on a new improved classifier to select patients with a higher likelihood of clinical response to treatment.

**Methods:** 75 patients with progressive, unresectable stage III or stage IV M1a MAGE-A3 (+) melanoma, were randomized as 1st line therapy between immunization with MAGE-A3 recombinant protein combined with GSK Adjuvant Systems AS15 or AS2B. Gene expression profiling was performed on tumor biopsies taken prior to any immunization.

**Results:** Supervised classification experiments were conducted on a subset of 62 patients. A multivariate gene selection process was embedded in the estimation of a mathematical predictive model (linear support vector machine). Using bootstrap resamplings, gene selection was repeated on 30 independent sample sets. A final gene signature of 33 probes was derived from genes appearing most frequently after the various resamplings. The vast majority of the identified genes are immune-related. The final classifier correctly predicts clinical response with 91% sensitivity, 95% specificity and 91% positive predictive value. These performances were estimated on new independent resamplings of the same data.

**Conclusions:** The gene signatures found in metastatic melanoma patients are strongly correlated with the response to the MAGE-A3 ASCI treatment, reflecting an immune microenvironment in the tumor present prior to any therapeutic intervention. Such signatures and associated classifier could be used to select patients with a higher likelihood of response to MAGE-A3 ASCI treatment.

**Results:** Study of tumor samples from pts in the placebo arm led to identification of a prognostic gene profile (GP) associated with a high risk of postoperative relapse. The absence of this profile correlated with a very low relapse rate in stage IB pts: placebo 0%; MAGE-A3 4%. In the MAGE-A3 treated pts with the high risk of relapse signature, we compared 10 stage IB pts with recurrence to 10 pts without recurrence. A 25-gene probe predicted benefit from MAGE-A3 treatment. The relevance of this signature was confirmed first on the remaining 139 stage IB and secondly on stage II biopsies. The hazard risk (HR) for disease-free interval in the ASCI arm was 0.57 and 0.78 in the GP+ and GP- groups, respectively, with no impact on relapse rate in the placebo arm. Immune related genes associated to the tumor microenvironment prior to treatment seem critical.

**Conclusions:** We identified prognostic markers associated with high risk of relapse. Stage IB pts with tumors expressing markers in the high risk of relapse signature results in a 2 fold increase in clinical efficiency. This signature is also associated to clinical activity of MAGE-A3 in a Phase II study in metastatic melanoma. Data will be validated in the ongoing NSCLC adjuvant phase III study (MAGRIT).

**1310 TP53 AND KRAS MUTATIONS AS MARKERS OF OUTCOME OF ADJUVANT CISPLATIN-BASED CHEMOTHERAPY IN COMPLETELY RESECTED NON-SMALL-CELL LUNG CANCER (NSCLC): THE INTERNATIONAL ADJUVANT LUNG CANCER TRIAL (IALT) BIOLOGICAL PROGRAM**

X. Ma1, A.L. Vataire2, H. Sun3, A. Durand2, E. Brambilla4, J. Soria5, M. Filipits6, P. Therasse7

1Molecular Carcigenogenesis and Biomarkers Group, International Agency for Research on Cancer, Lyon/FRA, 2Biostatistics, Institut Gustave Roussy, Villejuif/FRA, 3Epigenetics Group, International Agency for Research on Cancer, Lyon/FRA, 4Pathology, CHU Grenoble, Grenoble/FRA, 5Institute Gustave Roussy, Villejuif/FRA, 6Department of Medicine I, Medical University Vienna, Vienna/AUSTRIA

**Background:** Adjuvant cisplatin-based therapy improves survival among patients with completely resected NSCLC, but there is a lack of biological predictors of the benefit. We have analyzed mutations in TP53 (exons 5 to 8) and KRAS (codons 12 and 13) in archived specimens of patients enrolled in IALT, a randomized trial of adjuvant cisplatin-based chemotherapy against observation.

**Methods:** Genomic DNA was extracted from 738 paraffin-embedded sections. Mutations were detected by direct sequencing and independently confirmed by a second sequencing for TP53 or by Restriction Fragment Length Polymorphism (RFLP) for KRAS. Prognostic and predictive analyses were based on Cox models adjusted for clinical and pathologic variables.

**Results:** TP53 mutations were found in 240 of 324 patients (46%) for whom exons 5 to 8 could be entirely sequenced. TP53 mutation status had no prognostic or predictive value for survival in all NSCLC grouped together. However, in non-adenocarcinoma patients, there was a borderline significant interaction between TP53 status and treatment effect on disease-free survival (DFS) (test for interaction TP3 and treatment, p=0.05 and p=0.25 for overall survival (OS)). The effect of chemotherapy was not different in TP53 mutated and wild type patients (p=0.18 for DFS and p=0.15 for DFS), but a trend of benefit in TP53 mutated patients was observed. The prevalence of KRAS mutation was 14% (98/718). The prognostic effect of KRAS on DFS was different among the 3 histology groups, adenocarcinoma, squamous cell carcinoma and non-adenocarcinoma/ non-squamous cell carcinoma (p=0.03 for DFS and p=0.31 for OS), with the worst prognostic effect in the latter. Mutation of KRAS was not predictive of the effect of chemotherapy.

**Conclusions:** Patients with non-adenocarcinoma and TP53 wild type might benefit from cisplatin-based adjuvant chemotherapy, whereas chemotherapy might be harmful in patients with mutated TP53. KRAS mutation might be a biomarker of poor prognostic factor in patients with non-adenocarcinoma. Mutation detection may help in assigning patients to appropriate treatment protocol.
IGF-IR MARKERS IN NSCLC PATIENTS ON ANTI-IGF-IR THERAPY

A. Gualberto1, C.L. Melvin2, A. Dean3, A.L. Ang4, J. Reynolds5, A.V. Lee6, L.W. Terstappen7, P. Haluska8, A. Lipton9, D.D. Karp10

1Department of Cardiovascular and Metabolic Diseases, Pfizer Global Research and Development, New London/UNITED STATES OF AMERICA, 250 Pequot Avenue, Pfizer Global Research and Development, New London/UNITED STATES OF AMERICA, 350 Pequot Avenue, Pfizer Global Research and Development, New London/UNITED STATES OF AMERICA, 4MD Anderson Cancer Center, University of Texas, Houston/UNITED STATES OF AMERICA, 5Proteomics, HistofRx Inc., New Haven/UNITED STATES OF AMERICA, 6Department of Dna Sequencing, Pfizer Global Research and Development, Groton/UNITED STATES OF AMERICA, 7Department of Oncology, Mayo Clinic College of Medicine, Rochester/UNITED STATES OF AMERICA, 8Medical Oncology, Penn State Milton S. Hershey Medical Center, Hershey/UNITED STATES OF AMERICA, 9Department of Thoracic/head and Neck Medical Oncology, MD Anderson Cancer Center, Houston/UNITED STATES OF AMERICA

Background: The insulin-like growth factor type I receptor (IGF-IR) is potently and specifically inhibited by CP-751,871 (I), a fully human IgG2 subtype monoclonal antibody.

Methods: To assess the safety and efficacy of the combination of paclitaxel (T), carboplatin (C) and I as first-line treatment of advanced non-small cell lung cancer (NSCLC) patients, blood and tissue markers of the IGF-IR pathway were comprehensively evaluated during the conduct of phase I/II studies. Expression of IGF-IR and its ligands was also assessed in archival samples using tissue arrays and AQUA technology. IGFIR gene scanning was performed. Circulating tumour cells (CTCs) expressing the IGF-IR were enumerated using CellTracks™. Serum markers investigated included cleaved circulating IGF-IR, total and free IGF-I, IGFBP-3 and acid-labile subunit (ALS). Glycaemia was evaluated using fasting glucose. Human growth hormone (hGH) and insulin levels were determined in a cohort of patients treated with single agent I.

Results: Blood and/or tissue samples were obtained from 190 NSCLC patients. Tissue markers were further investigated in 178 archival NSCLC specimens. Tumour IGF-IR expression was most pronounced in squamous cell carcinoma in concert with a high objective response rate (72%) to TCI in that histology. Two somatic mutations were identified in the beta subunit of the IGF-IR tyrosine kinase domain, one translated into blockade of ligand-induced receptor autophosphorylation in functional studies. CTCs expressing IGF-IR were cleared from blood on TCI treatment and in some patients reappeared on disease progression. Circulating IGF-IR decreased, and IGF-1, IGFBP3 and ALS levels increased in serum in response to I treatment in a dose-dependent manner. Importantly, sustained IGF-1 levels were observed at higher I doses, consistent with systemic IGF-IR downregulation. Manageable and reversible hyperglycaemia (glucose >250 mg/dL) that was independent of glucose levels at enrolment was seen in 11% of NSCLC patients receiving TCI. hGH and glucose oscillated in parallel suggesting that hGH may play a role in the pathogenesis of I-induced hyperglycaemia.

Conclusions: Biomarkers of the IGF-IR pathway are integral to anti-IGF-IR therapy development and monitoring.
breast cancer, advanced

CAPECITABINE VS. CAPECITABINE + TRASTUZUMAB IN PATIENTS WITH HER-2 POSITIVE METASTATIC BREAST CANCER PROGRESSING DURING TRASTUZUMAB TREATMENT – THE TBP PHASE III STUDY (OGB 26 / BIG 3-06)

G. von Minwalla, C. Zielinski, M. Schmidt, D. Noh, Y. Bang

Background: There is uncertainty, if trastuzumab treatment should be continued beyond progression (TPB).

Methods: Patients (pts) with HE-2 positive, locally advanced or metastatic breast cancer that progressed during treatment with trastuzumab with or without ado-trastuzumab and/or 1st-line metastatic chemotherapy were prospectively randomized to capecitabine alone (X) or X plus continuation of trastuzumab (XH; 6 mg/kg, q3w). The primary end point was TTP. With registration of lapatinib, the slowly accruing trial was closed prematurely.

Results: Between 01/04 and 05/07 156 pts (X=78; XH=78) were randomized and stratified according to pre-treatment: Taxan/neoadjuvant chemotherapy (111 pts), taxanes/trastuzumab as adjuvant therapy (3 pts), trastuzumab alone or without taxanes as 1st-line treatment (42 pts). 7.5 (48.1%) pts were pre-treated with anthracyclines. 119 (76.3%) showed visceral metastases. The final analysis after a median follow-up of 16.6 months revealed a time to progression of 5.6 months with 65 events for X compared to 8.2 months with XH (HR=0.69; CI: (0.49, 0.99), log rank p=0.047). Brain metastases were observed in 3 (X) and 8 (XH) pts. Overall survival was 20.4 months with 38 events for X and 25.5 months with 33 events for XH (HR=0.77). Response rates were 26.7% (X) and 48.1% (XH) and the probability of BrM is read along the Total Points scale. The cross-validation of the development set predicted future BrM in 58% of patients, and the probability of BrM is read along the Total Points scale. The cross-validation of the development set predicted future BrM in 58% of patients, and created a nomogram that could be used for individual prediction. The model developed BrM. Young age, histological characteristics, number of metastatic lymph nodes, short disease-free survival, and number of metastatic sites were significantly and independently associated with subsequent BrM. The Nomogram will be presented at the meeting. For each parameter, points are determined on a specific scale, added, and the probability of BrM is read along the Total Points scale. The cross-validation showed that the mean error was 0.8%. In the validation set, BrM probabilities were well predicted with less than 5% difference between the predicted and observed proportions for each quartile.

Conclusion: We developed a robust tool to predict subsequent BrM in patients with MBC. A prospective randomized study is in progress to confirm these results and test the effect of prophylactic treatment.

A NOMOGRAM TO PREDICT SUBSEQUENT BRAIN METASTASIS IN METASTATIC BREAST CANCER (MBC) PATIENTS

N.C. Ibrahim, B. Abdulkarim, L. Hiu, L. Pusztai, E.A. Strom, G.N. Hortobagyi

Background: The development of brain metastases (BrM) is usually a terminal event in the clinical course of breast cancer patients with metastatic disease other than brain (MDOB). We hypothesized that occurrence of BrM can be predicted in patients with MDOB, thus allowing preventive intervention such as prophylactic brain radiation.

Methods: Patients with MBC treated between 2000 and February 2007 at M.D. Anderson Cancer Center were included in this retrospective analysis. We tested 20 variables and developed a multivariable model to predict occurrence of subsequent BrM and created a nomogram that could be used for individual prediction. The model was cross-validated by bootstrapping and tested in two independent cohorts consisting of 128 patients with MDOB treated at the Cross Institute, Edmonton, Canada, and 91 patients with BrM treated at the Hopital Tenon, France.

Results: Among 2136 patients with metastatic breast cancer, 362 subsequently developed BrM. Young age, histological characteristics, number of metastatic lymph nodes, short disease-free survival, and number of metastatic sites were significantly and independently associated with subsequent BrM. The Nomogram will be presented at the meeting. For each parameter, points are determined on a specific scale, added, and the probability of BrM is read along the Total Points scale. The cross-validation showed that the mean error was 0.8%. In the validation set, BrM probabilities were well predicted with less than 5% difference between the predicted and observed proportions for each quartile.

Conclusion: We developed a robust tool to predict subsequent BrM in patients with MBC. A prospective randomized study is in progress to confirm these results and test the effect of prophylactic treatment.

RESULTS OF FDG-PET/CT AFTER FIRST CYCLE OF NEOADJUVANT CHEMOTHERAPY REFLECT TUMOR CHARACTERISTICS IN BREAST CANCER: POSSIBLE VALUE OF SUV CHANGES DURING CHEMOTHERAPY IN PREDICTION OF TUMOR BIODcription and CARACTER and OF PATHOLOGIC PARAMETERS

Y. Koh, B. Keem, S. Im, K.W. Kang, D. Oh, W. Han, T. Kim, I.A. Park, D. Noh, Y. Bang

Background: Breast cancer is a heterogenous disease that shows different biologic behavior according to its subtypes. We analyzed the clinical significance of FDG-PET/CT in terms of clinico-pathologic parameters in stage II and III breast cancer patients who received neoadjuvant chemotherapy.

Methods: Between July 2006 and December 2007, a total of 52 stage II and III breast cancer patients (median age: 46) who received neoadjuvant docetaxel/doxorubicin chemotherapy were enrolled in this prospective study. The patients received three cycles of neoadjuvant chemotherapy followed by surgery and received three more cycles of docetaxel/doxorubicin chemotherapy as an adjuvant. Quantitative FDG PET/CTs were acquired before chemotherapy and after the first cycle of chemotherapy for breast cancer.

© The Author 2008. Published by Oxford University Press on behalf of the European Society for Medical Oncology. All rights reserved. For permissions, please email: journals.permissions@oxfordjournals.org
docetaxel 75 mg/m² (DE) on day 1 or docetaxel 75 mg/m² on day 1 plus capecitabine 950 mg/m² (DC) in cycles every 21 days. Patients who had received anthracycline-based adjuvant or neoadjuvant chemotherapy more than one year before were allowed to participate. The primary end point of the study was to compare the time to disease progression (TTP).

**Results:** A total of 272 women were randomized to DE (n=136) and DC (n=136). All patients were evaluable for treatment toxicity and efficacy. Sixteen vs 18 patients were premenopausal, 15 vs 18 had stage IIIB disease, 3 vs 4 had performance status 2, 27 vs 35 had previously received (neo) adjuvant anthracycline-based treatment on DE vs DC arms, respectively. We observed 15(11%) vs 11(8%) complete responses and 55(40%) vs 61(43%) partial responses for an overall response rate of 51.3% vs 52.9% (p=0.01) in DE vs DC arms, respectively. The median duration of response was 10.4 vs 13.4 months (p=0.9) and the median TTP 10.4 vs 10.5 months (p=0.9) for DE and DC arms, respectively. A total of 803 DE vs 796 DC cycles were administered with 1 vs 13.4 months (p=0.9) and the median duration of response was 10.4 vs 13.4 months (p=0.07). Freible neutropenia 11% vs 8% (p=0.04), hand-foot syndrome 0% vs 3% (p=0.02), grade 2-3 anemia 20% vs 7% (p=0.01), diarrhea 6% vs 9% (p=0.02) and asthenia 13% vs 7% (p=0.06).

**Conclusions:** The DE and DC regimens have similar efficacy but different toxicity. Either regimen can be used as front-line treatment of women with ABC.

---

**137P A RANDOMIZED STUDY OF THE EFFICACY AND SAFETY OF LACATINIB IN COMBINATION WITH TRASTUZUMAB AND AS MONOTHERAPY AFTER PROGRESSION ON TRASTUZUMAB IN HEAVILY PRETREATED ERBB2+ METASTATIC BREAST CANCER (MBC)**

**K.L. Blackwell, 1 H.J. Burstein, 2 A.M. Storniolo, 3 H. Rugo, 4 G. Sledge, 5 M. Koehler, 4 C. Ellis, 5 M. Casey, 3 J. Baselgia, 3 J. D’Ouignhuyssen**

1Medical Oncology, Dana-Farber Cancer Institute, Boston/UNITED STATES OF AMERICA, 2Medical Oncology, Duke University Medical Center, Durham/UNITED STATES OF AMERICA, 3Medical Oncology, University of California, San Francisco/UNITED STATES OF AMERICA, 4Medical Oncology, Indiana University Cancer Center, Indianapolis/UNITED STATES OF AMERICA, 5Medical Oncology, Dana-Farber Cancer Center, Boston/UNITED STATES OF AMERICA, 6Medical Oncology, Dana-Farber Cancer Institute, Boston/UNITED STATES OF AMERICA, 7Medical Oncology, Dana-Farber Cancer Center, Boston/UNITED STATES OF AMERICA, 8Medical Oncology, Dana-Farber Cancer Institute, Boston/UNITED STATES OF AMERICA, 9Medical Oncology, Dana-Farber Cancer Center, Boston/UNITED STATES OF AMERICA, 10Medical Oncology, Dana-Farber Cancer Institute, Boston/UNITED STATES OF AMERICA.

**Purpose:** Lapatinib (Tyverb/Tykerb®) an oral, small molecule inhibitor of ErbB2 and ErbB1 has a mechanism of action distinct from trastuzumab (T). L showed synergy with T in preclinical models and has established efficacy in patients (pts) with ErbB2+ MBC that progressed on T. Here L was studied alone and with T in pts with ErbB2+ MBC that progressed on T.

**Methods:** Eligible pts had prior anthracycline and taxane therapy, stage IV BC and progressed recently on prior T-containing regimen. Pts were stratified by receptor and visceral disease status then randomized to receive L (1500 mg QD) or L (1000 mg QD) plus T (2 mg/kg weekly after 4 mg/kg loading dose). Crossover was allowed after progression on L arm. The primary endpoint was PFS analyses also were conducted in ITT subgroups based on metastatic site.

**Results:** 296 pts were randomized. All pts progressed on prior T; the median number of prior regimens was 6; 73% had visceral disease. PFS is summarized in Table 1. CRR was 24.7% in L+T arm and 12.4% in L arm (OR: 2.2; 95% CI: 1.2, 4.5; p=0.01), although data are not mature, a trend in improved OS was seen in pts treated with L+T (p=0.106). Grade 1/2 diarrhea was higher in the L+T arm; rash was more common in the L alone arm. Asymptomatic decline in LVEF was seen in 0.6% of L+T and 1.4% of L pts. cardiac related death occurred in the L+T arm. PFS in ITT

**Population (N) HR L+T/ L 95% CI Stratified log-rank p-value**

<table>
<thead>
<tr>
<th>Overall (296)</th>
<th>0.77</th>
<th>0.70</th>
<th>0.029</th>
</tr>
</thead>
<tbody>
<tr>
<td>Visceral (211)</td>
<td>0.71</td>
<td>0.5, 0.9</td>
<td>0.014</td>
</tr>
<tr>
<td>Nonvisceral (80)</td>
<td>0.97</td>
<td>0.9, 1.0</td>
<td>0.894</td>
</tr>
<tr>
<td>Bone (156)</td>
<td>0.70</td>
<td>0.5, 1.0</td>
<td>0.035</td>
</tr>
<tr>
<td>Skin (52)</td>
<td>0.96</td>
<td>0.3, 1.0</td>
<td>0.007</td>
</tr>
<tr>
<td>CNS (34)</td>
<td>0.62</td>
<td>0.3, 1.2</td>
<td>0.132</td>
</tr>
</tbody>
</table>

**Conclusions:** L+T prolonged PFS in the overall and in several subgroup populations. This study represents the first randomized, phase III trial investigating the clinical benefit of 2 targeted agents in ErbB2+ MBC and supports the synergy observed in preclinical studies. Clinical benefit was meaningful with the combination and monotherapy despite pts progressing on prior T therapy. Both treatment arms were generally well tolerated. The role of combined anti-ErbB2 therapy in pts with less advanced disease is tested in the ALTTO study.

---

**39P LAPATINIB PLUS TRASTUZUMAB VERSUS LAPATINIB MONOTHERAPY IN TRASTUZUMAB-REFRACTORY ERBB2+ METASTATIC BREAST CANCER (MBC) PATIENTS (PTS): QUALITY OF LIFE (QOL) ASSESSMENT**

**H.J. Burstein, 1 Y. Wu, 5 K. Blackwell, 5 A.M. Storniolo, 5 H. Rugo, 5 M. Amarikaz, 5 C. Ellis, 5 G. Sledge, 3 J. Baselgia, 3 J. D’Ouignhuyssen**

1Medical Oncology, Dana-Farber Cancer Institute, Boston/UNITED STATES OF AMERICA, 2Global Health Outcomes, RTI, Research Triangle Park/UNITED STATES OF AMERICA, 3Medical Oncology, Duke University Medical Center, Durham/UNITED STATES OF AMERICA, 4Medical Oncology, Indiana University Cancer Center, Indianapolis/UNITED STATES OF AMERICA, 5Comprehensive Cancer Centre, University of San Francisco, San Francisco/UNITED STATES OF AMERICA, 6Medical Oncology, Indiana University Cancer Center, Indianapolis/UNITED STATES OF AMERICA, 7Medical Oncology, University of California, San Francisco/UNITED STATES OF AMERICA, 8Medical Oncology, Dana-Farber Cancer Institute, Boston/UNITED STATES OF AMERICA, 9Medical Oncology, Dana-Farber Cancer Institute, Boston/UNITED STATES OF AMERICA, 10Medical Oncology Department, Vall d’Hebron University Hospital, Barcelona/SPAIN, 11Texas Oncology, Baylor Sammons Cancer Center, Houston/UNITED STATES OF AMERICA

**Purpose:** Women with ErbB2+ MBC who had documented progression on at least 1 trastuzumab (T)-containing regimen in the metastatic setting were treated in a phase III randomized, open-label study with either lapatinib (L) plus T or T alone. Crossover was allowed after progression on L arm. This analysis focuses on impact of treatments on health-related QOL.

**Methods:** QOL was assessed using the Functional Assessment of Cancer Therapy-Breast (FACT-B) questionnaire. Outcome measures included FACT-B total score, FACT-general (FACT-G) score and trial outcome index (TOI). Higher scores indicate better QOL. The questionnaire was completed at baseline, weeks (wks) 4, 12, 16, then every 6 wks and at therapy discontinuation. Changes from baseline scores were analyzed in the ITT population using analysis of covariance with baseline value as a covariate. Analyses based on observed data and also using the last observation carried forward (LOCF) method was performed.

**Results:** Women with ErbB2+ MBC, a median of 6 previous chemotherapy regimens and who were treated with L+T had significantly prolonged PFS (HR: 0.77; 95% CI: 0.6, 10; p = 0.029). The clinical benefit rate (CRR+SD for 6 mths) with L+T was 24.7% (12.4% in L arm). Baseline QOL assessment in both arms (N=148/arm) was completed in >95% of patients. Approximately 40% of patients in the L+T arm (36% in L arm) completed the wk 12 assessment; 20% in both arms completed the wk 24 assessment. Differences in adjusted mean change from baseline for L+T vs. L alone for observed data are presented below. Results using the LOCF approach were comparable to results using observed data.

**Pazopanib + Lapatinib is more active than Lapatinib alone: updated results from a randomized study in patients with erbB2 positive advanced or metastatic breast cancer**

**D. Slamovici, 1 H. Gommez, 2 O. Amrit, 4 M. Richie, 3 L. Pandite, 4 D. Roychowdhury, 2 P. Goodman**

1Division of Hematology/oncology, Jonsson Comprehensive Cancer Center UCLA School of Medicine, Los Angeles/UNITED STATES OF AMERICA, 2Medical Oncology Department, Instituto Nacional de Enfermedades Neoplasicas, Lima/PERU, 3Scientific Communications, GlaxoSmithKline, Collegeville/UNITED STATES OF AMERICA, 4Oncology, GlaxoSmithKline, Research Triangle Park/UNITED STATES OF AMERICA

**Background:** Evidence indicates a direct molecular link between ErbB2 amplification and up-regulation of VEGF in ErbB2+ breast cancer. Concurrent over-expression of ErbB2 and VEGF is associated with a poorer clinical outcome than over-expression of either alone. VEGF may also play a role in resistance to ErbB2-directed therapy. These
A PHASE II TRIAL OF TRASTUZUMAB AND PERTUZUMAB IN PATIENTS WITH HER2-OVEREXPRESSING METASTATIC BREAST CANCER THAT HAD PROGRESSED DURING TRASTUZUMAB THERAPY: FULL RESPONSE DATA


1Medical Oncology, Service Vall d’Hebron, Barcelona/SPAIN, 2Department of Oncology, Vall d’Hebron Hospitals, Djon/FRANCE, 3Medical Oncology, Stottawa Regional Cancer Center, Ottowa/CANADA, 4Department of Medical Oncology, The Royal Marsden Hospital, Manchester/UNITED KINGDOM, 5Department Onc and Her, Univ de Medona Univ Hosp, Medona/ITALY, 6Oncology, RMount Vernon Cancer Centre, Middlesex/UNITED KINGDOM, 7Medical Oncology, 1, Fornazione IICC’s Istituto Nazionale dei Tumor, Milan/ITALY, 8Roche Products Ltd, Roche Products Ltd, Welwyn Garden City/UNITED KINGDOM, 9Medical Oncology, British Columbia Cancer Agency, Vancouver/ CANADA

Background: Pertuzumab (P) is a humanised monoclonal antibody that binds to the same specific epitope of HER2, blocking both homo- and heterodimerisation, so inhibiting key HER signalling pathways that mediate cancer cell proliferation and survival. Trastuzumab (Herceptin1), H) binds to a different HER2 epitope and xenograft studies indicate that the complementary mechanisms of action of P and H have a synergistic effect when combined. This single-arm, two-stage study evaluates the efficacy and safety profile of P + H in P previously treated patients with HER2-positive metastatic breast cancer (MBC) that had progressed during H as most recent treatment for metastatic disease.

Methods: Eligible patients with measurable disease who had not responded to a previous dose of LVEF to <50% during previous H therapy and a baseline LVEF between 50% and 70% will be recruited. Patients will be randomised to Receive P 400 mg/d or L 1800 mg/d for 12 weeks. As a result of a previous dose of LVEF to <50% during previous H therapy and a baseline LVEF between 50% and 70% will be recruited. Patients will be randomised to receive P 400 mg/d or L 1800 mg/d for 12 weeks. Each cohort of 15 patients will be followed for at least 24 weeks. The primary endpoint is progression-free survival (PFS) of at least 6 months. Secondary endpoints include overall survival (OS), progression-free survival (PFS), and safety. A minimum of 40 patients will be enrolled to allow for the primary analysis of PFS.

Results: As of the cutoff date of 28th February 2008, 48 patients have been enrolled. The safety profile of P + H was evaluated in 28 patients, with a median follow-up of 11 weeks (range 4-28 weeks). No new toxicities were observed in P + H compared to H alone. The most common adverse events (AEs) in patients receiving P + H (n=28) were diarrhea (43%), fatigue (32%), nausea (29%), and vomiting (29%). Two grade 3 AEs were reported: one patient with a grade 3 diarrhea and one with a grade 3 neutropenia. There were no grade 4 or higher AEs reported. The median progression-free survival (PFS) for patients receiving P + H was 6.4 months (95% CI 2.9-10.8) compared to 2.8 months (95% CI 1.4-4.2) for patients receiving H alone. The median overall survival (OS) for patients receiving P + H was 16.4 months (95% CI 10.8-22.0) compared to 10.2 months (95% CI 7.4-13.0) for patients receiving H alone. These results demonstrate that the combination of P + H is well tolerated and shows promising activity compared to H alone.

Conclusion: The combination of P + H is well tolerated and has improved activity vs. L. Further evaluation in larger trials is warranted to confirm these results.
LAPATINIB EXPANDED ACCESS PROGRAM (LEAP): UPDATED SAFETY DATA

S. de Placido1, G. Capri2, J. Roiz, S. Danesi3, S. Chen4, J. Bymre5, J. Rosenlund6, M. Gress1, C. Oliva1, R. Park1
1Medical Oncology, University of Napoli Federico II, Naples/ITALY, 2Oncology, Instituto Nazionale per lo Studio e la Curia dei Tumori, Milan/ITALY, 3Oncology, National Cancer Center South Korea, Guryeong/KOREA, 4Oncology, 4Ospedale Ostetrico Ginecologico Sant'Anton, Torino/ITALY, 5Oncology, Chang Gung Memorial Hospital, Taipai/TAIWAN, 6Oncology, GSK, Collegeville/UNITED STATES OF AMERICA, 7Oncology, GSK, Stockley Park/UNITED KINGDOM, 8Medical Oncology, Università di Napoli Federico II, Stockley Park/UNITED KINGDOM

Enrollment in the Phase III trial of lapatinib and capecitabine vs capecitabine alone (EGF00151) was halted on 3 April 2016, after interim analysis data were evaluated by the IDMC and a marked improvement in time to progression, the primary endpoint, was found in the lapatinib and capecitabine arm. GlaxoSmithKline organized a global Lapatinib Expanded Access Program (LEAP) to provide pre-approval access to lapatinib for patients who presented with recurrent breast cancer after the study was halted. Design: issue, enrollment, and updated safety data are presented. Results: LEAP is a worldwide program that was designed to provide access to lapatinib to a slightly broadened patient population compared with the EGF00151 clinical trial. A clinical trial study was chosen over a named patient format to assist with equal access. Unlike EGF00151, LEAP allows enrollment of patients with metastatic disease, with ECOG PS 0-3, with no prior treatment, with a previous episode of anti-HER2 therapies. All pts received induction CT with 6 cycles of A-T (50/75 mg/m2/q21d). Pts with a complete or partial response (CR, PR), or stable disease (SD) were eligible. Pts were randomized to receive either pegylated liposomal doxorubicin (PLD, Cadexom®) 40 mg/m2 q28d x 6 cycles or observation (O). Primary endpoint was time to progression (TTP); secondary endpoints included toxicity and overall survival (OS). We assumed an increase of median TTP of 68% (log-rank test) with maintenance PLD. With an alpha error of 0.01 (1-sided) and a power of 80%, 77 patients per arm were needed. Statistical analysis was performed on intent to treat population. Results: Of 288 pts registered, 155 were randomized (78 PLD, 77 O). Median age was 57 years (range 30-74). Disease status of pts following induction therapy and at randomization to PLD vs O: CR 4% vs 9%, PR 49% vs 61%, SD 47% vs 30%. Median number of PLD cycles was 6 (range 0-6). Median TTP from randomization was 8.32 mo with PLD vs 4.93 mo with O (p=0.008). Median TTP from initial induction treatment was 13.18 mo with PLD vs 10.06 mo with O (p=0.005). At 12 mo. 81% of PLD pts and 66% of O pts were alive (p=0.04). LVEF dropped below 50% in 2 pts in PLD group vs none in O group, 5 pts in PLD group vs 1 pt in O group had a LVEF decline of 10 or more percentage points. There were no cases of congestive heart failure in either group. Grade 3 hand-foot syndrome occurred in 4% of pts in the PLD group. Other grade 3/4 toxicities between treatment arms were unremarkable. Conclusion: Maintenance CT with PLD in MBC pts after induction CT significantly prolongs TTP, with no late cardiotoxicity. Overall survival data will be presented.

Discordances in HER2 overexpression among primary breast cancer, autologous metastases and metachronous contralateral breast cancer

G. Metro1, A. Di Benedetto2, A. Fabi3, P. Papaldo1, P. Vici1, C. Nistico4, B. Antoniani2, E. Melucci2, F. Cognetti4, M. Mottolese2
1Medical Oncology, Regina Elena Cancer Institute, Rome/ITALY, 2Pathology, Regina Elena Cancer Institute, Rome/ITALY, 3Oncology, Regina Elena Institute, ROMA/ITALY, 4Medical Oncology, Regina Elena National Cancer Institute, Roma/ITALY

Background: It is unclear to what extent primary breast cancer (PBC) is representative of metastases in terms of HER2 expression. Aim of the present study were to relate HER2 status of PBC with HER2 expression of the corresponding metastatic site as well as with HER2 expression of metachronous contralateral primary breast cancer (CLBPC). Methods: Tissue microarrays constructed from surgical specimens of 157 PBC (134 ductal and 23 lobular), 80 corresponding metastases (11 visceral and 25 non visceral diseases, 44 breast recurrences) and 77 CLBPC were stained for HER2 (Dako HercepTest). Median age of patients was 52 years (26-82), hormonal receptors (HR) were positive in 91 (58%) tumors. Ninety-two (58%) and 72 (46%) patients had undergone prior chemotherapy and hormonal therapy respectively. No patients had received prior trastuzumab as adjuvant therapy. Results: Discordance in HER2 expression between PBC and metastases was found in 12/90 cases (13%) and in 25/77 CLBPCs (32%). More specifically, HER2 was negative (0/1+) in PBC and positive (2+/3+) in metastases in 8 (10%) cases and it was positive (2+/3+) in PBC and negative (0/1+) in metastases in 4 (5%) patients (p=0.04). Concerning CLBPC, HER2 was negative in PBC and positive in CLBPC in 11/18 cases (61%) and positive in PBC and negative in CLBPC in 14 (18%) cases (p=0.9). HR positive PBC showed no significant difference in HER2 expression between PBC and metastases as compared to H R negative PBC. (17% vs 13%, p=0.12). Conversely, HER2 discordance between PBC and CLBPC was significantly higher in HR negative than HR positive (57% vs 28% p= 0.02). Conclusion: in patients with HER2 negative early breast cancer, HER2 status should be reassessed in the metastatic tissue at the time of disease progression, since changes in HER2 expression (from negative to positive) may occur in a significant percentage of patients. Detecting these modifications increases the chances of identifying patients with MBC from anti-HER2 therapies. The high discordance between PBC and CLBPC is consistent with the fact that PBC and CLBPR often represent two phenotypically distinct diseases.
Annals of Oncology
term disease stabilization (SD24 weeks), for an overall clinical benefit of 68% (95% CI 51-81%). Median time to progression was 42 weeks (95% CI 26-72). Treatment was well tolerated. Grade 3/4 side effects included: hypertension (8 patients), leucopenia (2), neutropenia (2), transaminitis (2), protE-transferrin (1), nausea (1), vomiting (1). All side effects were manageable and reversible. Baseline total circulating endothelial cells (CEC) count and viable CEC count were both significantly increased in patients who achieved a clinical response (p=0.02 and p=0.02, respectively) and a clinical benefit (p=0.01 and p=0.03, respectively). Viable CEC count was related to total CEC count (correlation index 0.97); a similar correlation was found between apoptotic and total CEC count. Patients who had ≥27 baseline apoptotic CECs/µL (25th percentile distribution value) had a significantly better progression-free survival (p=0.04).

Conclusions: Metronomic capetitabine and cyclophosphamide combined with bevacizumab provide long-term disease control in MBC, with no significant toxicity. Baseline CEC count was related to response, and might represent an indirect measure of the angiogenic turnover, suggesting further studies on this surrogate marker for the selection of patients candidates to anti-angiogenic treatments.

147P QUALITY OF LIFE (QOL) AMONG PATIENTS (PTS) WITH LOCALLY RECURRENT (LR) OR METASTATIC BREAST CANCER (MBC): RESULTS FROM THE PHASE III AVADO STUDY OF FIRST-LINE BEVACIZUMAB (BV) PLUS DOCETAXEL (D) VERSUS D PLUS PLACEBO (PL)

R. Freitas-Júnior7, P. Fumoleau8, V. Sriuranpong9, D.W. Miles10

1Medical Department, Medical University of Salzburg, Salzburg/AUSTRIA, 2Department of Internal Medicine, Samsung Medical Center, Seoul/KOREA, 3Clinic of Breast Cancer and Reconstructive Surgery, Maria Sklodowska-Curie Cancer Center, Warsaw/POLAND, 4Department of Medical Oncology, Christie Hospital, Manchester/UNITED KINGDOM, 5Medical Oncology, Jules Bordet Institute, Brussels/BELGIUM, 6Medical Department, Hospital 12 De Octubre, Madrid/SPAIN, 7Gaïs AntiCancer Association, Araoujo Hospital, Goinia/BRAZIL, 8Medical Department, Centre Georges-François-Leclerc, Dijon/FRANCE, 9Medical Oncology Unit, Dept of Medicine, Faculty of Medicine, Chulalongkorn University, Bangkok/THAILAND, 10Oncology, Mount Vernon Cancer Centre, Middlesbrough/UNITED KINGDOM

Background: The anti-VEGF therapy BV (Avastin®) has significantly improved overall and/or progression-free survival (PFS) in several tumour types. In the randomised, double-blind, placebo-controlled phase III AVADO study, two doses of first-line BV combined with D significantly improved PFS and response rates compared with D alone in pts with LR or MBC. BV has only limited impact on the known safety profile of 100mg/m² docetaxel. Here we present QoL data.

Methods: Pts with HER2-negative LR or MBC, ECOG PS 0–1, adequate LVEF and metastatic breast cancer (MBC) who have been pre-treated with anthracyclin in metastatic situation for patients (pts) having received anthracyclin in adjuvant setting with the risk to run on cardiotoxicity regarding anthracyclin cumulative dose. The objective of the study is to evaluate efficacy and safety of Myocet™ (M) and D as frontline chemotherapy in her2-neu negative metastatic breast cancer (MBC) who have been pre-treated with anthracyclin in adjuvant setting.

Methods: Eligible pts were > 18 years, with MBC relapsing at least 12 months after previous anthracyclin and/or taxan, WHO performance status 0-1-2, left ventricular ejection fraction(LVEF) > 50%, measurable target lesions, cumulative dose of doxorubicin or epirubicin or mitomycin are respectively under 366, 600, 75 mg/m² Treatment M=60mg/m² (96 min infusion) was followed by D=75 mg/m² (60 min infusion), qweeks for a minimum of 6 cycles. Clinical adverse events review, haematology assay were performed each cycle, LVEF every 2 cycles, tumor assessment was performed after 2 and 4 cycles.

Results: 36 pts with median age 56 (40-71) entered the study. All with metastatic lesions (liver 19, bone 15, lung 12, soft tissues 6, skin 3, pleural 2, multiple 18). Pneumonopausal 6 pts, negative hormonal receptors 5pts. A total of 212 M and D cycles were administered, G-CSF was used in 11 pts, Erythropoetin in 2 pts. No treatment related death has been reported. Grade 3-4 toxicity: febrile neutropenia 4 pts, neutropenia 6 pts, thrombocytopenia 2 pts, peripheral edema 1 pt. Cardiotoxicity: Mean baseline LVEF=57%, at median follow up 34 months, 38,8% after cycle 6. No PPE were noted. Efficacy: Overall Objective Response Rate (ORR)=58%, IC 95%(34-74) at median follow up 34 months (13-47): median PFS=11 months (4-36), median response duration: 18 months (2-33), median overall survival=24 months (3-45).

Conclusion: M and D combination shows a high overall response rate and prolonged survival time compare to previously published anthracyclines and taxanes combinations, with manageable hematologic toxicity and non significant changes in LVEF.

149P COMPARATIVE EFFICACY OF FIRST-LINE DOCETAXEL + CAPECTABINE (XT) VERSUS DOCETAXEL + EPIRUBICIN (ET): POOLED ANALYSIS OF TWO RANDOMISED TRIALS

L. Frei1, T. Facchin2, N. Dohollou3, P. Nouryegat4, A. Lortholary5, P. Gomez6, A. Lortois7, C. Bressac8, J. Gligorov9, D. Jaubert10

1Onco-hematology, Hopital Font-Pre`re, Toulon/FRANCE, 2, Centre de Radiothérapie, Reims/FRANCE, 3Radio-chemotherapy, Polyclusi`ne Bordeaux Nord Aquitaine, Bordeaux/FRANCE, 4Oncologie, Clinique du cap d’Or, La Seyne sur Mer/FRANCE, 5Oncologie, Centre Carmin, Saint-Cyr/Saint-Sauveur, France, 6Oncologie, Clinique Saint Hilaire, ROUEN/FRANCE, 7Oncology, Hopital Européen Georges Pompidou, Paris/FRANCE, 8Medical Oncology, Hôpital Tenon, Paris/FRANCE, 9Oncologie, Clinique Tivoli, Bordeaux/FRANCE, 10Oncology, Centre LEon Berard, Lyon/FRANCE

Background: First line docetaxel (D) and doxorubicin yield up to 55% response rates in previous studies, in relapse situation for patients (pts) having received anthracyclin in adjuvant setting with the risk to run on cardiotoxicity regarding anthracyclin cumulative dose. The objective of the study is to evaluate efficacy and safety of Myocet™ (M) and D as frontline chemotherapy in her2-neu negative metastatic breast cancer (MBC) who have been pre-treated with anthracyclin in adjuvant setting.

Methods: Eligible pts were > 18 years, with MBC relapsing at least 12 months after previous anthracyclin and/or taxan, WHO performance status 0-1, left ventricular ejection fraction(LVEF) > 50%, measurable target lesions, cumulative dose of doxorubicin or epirubicin or mitomycin are respectively under 366, 600, 75 mg/m² Treatment M=60mg/m² (96 min infusion) was followed by D=75 mg/m² (60 min infusion), qweeks for a minimum of 6 cycles. Clinical adverse events review, haematology assay were performed each cycle, LVEF every 2 cycles, tumor assessment was performed after 2 and 4 cycles.

Results: 36 pts with median age 56 (40-71) entered the study. All with metastatic lesions (liver 19, bone 15, lung 12, soft tissues 6, skin 3, pleural 2, multiple 18). Pneumonopausal 6 pts, negative hormonal receptors 5pts. A total of 212 M and D cycles were administered, G-CSF was used in 11 pts, Erythropoetin in 2 pts. No treatment related death has been reported. Grade 3-4 toxicity: febrile neutropenia 4 pts, neutropenia 6 pts, thrombocytopenia 2 pts, peripheral edema 1 pt. Cardiotoxicity: Mean baseline LVEF=57%, at median follow up 34 months (13-47): median PFS=11 months (4-36), median response duration: 18 months (2-33), median overall survival=24 months (3-45).

Conclusion: M and D combination shows a high overall response rate and prolonged survival time compare to previously published anthracyclines and taxanes combinations, with manageable hematologic toxicity and non significant changes in LVEF.

Purpose: Taxane-based combination therapies are the most active first-line regimens for metastatic breast cancer (MBC), but selection of the most appropriate treatment can be difficult. XT significantly improves response rate (RR), time to progression and overall survival (OS) compared with docetaxel alone, and in a recent phase III trial, capetitabine plus paclitaxel showed similar efficacy to epirubicin plus paclitaxel. Two French trials, ERASMUS-4 and CAPEDOC-EPIDOC,
aimed to compare the efficacy of first-line XT vs ET in MBC. Both were terminated prematurely due to poor accrual, but here are the study designs were so similar, we pooled available data to gain information on the relative efficacy of these regimens.

**Methods:** In both trials, patients (pts) who had received no chemotherapy for MBC received 3-weekly cycles of either XT (docetaxel 75 mg/m², etoposide 1000 mg/m² twice daily, d1-4) or ET (docetaxel 75 mg/m², epirubicin 75 mg/m², both d1; primary prevention of febrile neutropenia (FN) with growth factor support was recommended with ET). The primary endpoint was progression-free survival (PFS) rate in both trials. In ERASME, it was planned to recruit 106 pts, giving 95% power to test a 6-month PFS rate of 75% (XT) vs 60% (ET). Secondary endpoints included duration of PFS and OS.

**Results:** Between March 2003 and January 2007, 92 pts were enrolled in the two trials. Pt characteristics were well balanced between treatment arms; most had received adjuvant anthracycline therapy. Efficacy after median follow-up of 15 months is shown below.

<table>
<thead>
<tr>
<th>XT (n=45)</th>
<th>ET (n=47)</th>
<th>P value</th>
</tr>
</thead>
<tbody>
<tr>
<td>6-month PFS rate (95% CI)</td>
<td>78% (63-89)</td>
<td>74% (60-86)</td>
</tr>
<tr>
<td>Median PFS, months</td>
<td>12</td>
<td>9</td>
</tr>
<tr>
<td>Median OS, months</td>
<td>28</td>
<td>28</td>
</tr>
</tbody>
</table>

Toxicity was generally mild or moderate with only one episode of FN. Grade 3 hand-foot syndrome occurred in 17% of XT pts vs 0% of ET pts. Conclusion: These data confirmed that XT is an active first-line regimen and suggest that XT may extend PFS compared with ET. We consider XT to be a valid, non-anthracycline-containing alternative to ET in this setting.

**151P**

**AN INTERNATIONAL PHASE II STUDY OF AN ALL-ORAL COMBINATION OF ORAL VINORELBINE (NVBO) AND CAPECITABINE (X) IN HER2-NEGATIVE METASTATIC BREAST CANCER (MBC): LATEST RESULTS WITH A MEDIAN FOLLOW-UP OF 33.5 MONTHS**

N. Tubiana-Mattey1, P. Bougonoux2, D. Becquart2, A. Chan3, F. Majos3, M. Espié4, A. Llobart5, G. Villanova6, P. Conte6

1Medical Oncology, CHU DUPUYTREN, LIMOGES/FRANCE, 2Medical Oncology, CHU BRETIGNY/TOURS/FRANCE, 3Medical Oncology, AZ MIDDLEHEIM, ANTERWURPER/BELGIUM, 4Medical Oncology, MOUNT HOSPITAL, PERTH/AUSTRALIA, 5Medical Oncology, HOPITAL JOLIENNTE, HAINNE ST PAUL/BELGIUM, 6Medical Oncology, HOPITAL ST LOUIS, PARIS/FRANCE, 7Servicio De Oncologia Medica, Instituto Valenciano De Oncologia, Valencia/SPAIN, 8Medical Affairs Oncology, Pierre Fabre Medicament, Boulogne Billancourt/FRANCE, 9Dept Onc and Hem, Univ of Modena Univ Hosp, Modena/ITALY

**Background:** Oral chemotherapy (CT) is attractive for patients (pts) with MBC. The all-oral regimen of NVBo and X is active with good tolerability in MBC. We report an updated analysis of efficacy and safety from an international Phase II study of NVBo plus X.

**Methods:** Main eligibility criteria included: measurable HER2-negative, CT-naive MBC, relapse 6 months after completing (neo)adjuvant CT; Karnofsky PS ≥70, age ≥18 years. Study treatment: 3-weekly cycles of NVBo 80 mg/m² (after a first cycle at 60 mg/m²) d1 and d8, plus X 1000 mg/m² twice daily d1-4. Treatment was continued until progression or unacceptable toxicity.

**Results:** 55 pts were enrolled and 54 were treated: median age: 58.5 years (18% ≥65 years); prior (neo)adjuvant CT 63%; type of CT:anthracycline 67%, anthracycline + taxane 18%, CMF 15%; visceral involvement in 78%; >2 metastatic sites in 46%. Median duration of response was 7 months (95% CI [6-12]). Median progression-free survival was 12.8 months (95% CI [11-17]), overall survival results are not mature yet. Treatment is ongoing in 5 pts.

**Conclusion:** This trial results show, in patients with HER2-positive MBC, a high efficacy of the combination of NVBo and X plus H. This regimen can be safely administered for this patient population.

**152P**

**INTERIM RESULTS OF A PHASE II STUDY OF NAB-PACLITAXEL (TAXEL), BEVACIZUMAB, AND CAPECITABINE AS FIRST-LINE THERAPY FOR PATIENTS WITH HER2-NEGATIVE METASTATIC BREAST CANCER (MBC)**

S. Gluck, C. Lobo, J. Hurley, G. Lopes, I. Reis, P. Seo, O. Silva, J. Slingerland, C. Welsh, K. Tukia

Miller School of Medicine, Brigham Family Breast Cancer Institute, Miami/UNITED STATES OF AMERICA

In a phase III study in patients with MBC, nab-paclitaxel (Abraxane®) demonstrated nearly double the overall response rate (P = 0.006) versus solvent-based paclitaxel (ICO. 2005;23:7794-7803). Improvement in time to progression and response rates have also been demonstrated when solvent-based paclitaxel was combined with gemcitabine (Gemzar®) or bevacizumab (Avastin®). The current study is the first to examine the efficacy and safety of combination therapy with nab-paclitaxel, bevacizumab, and gemcitabine for first-line treatment of patients with MBC. Patients (≥ 18 years with untreated HER2-negative MBC or metastases diagnosed <26 months after primary systemic treatment) received gemcitabine 1500 mg/m², nab-paclitaxel 150 mg/m², and bevacizumab 10 mg/kg (each administered intravenously over 30 minutes) on days 1 and 15 of 28-day cycles. Cycles were repeated for the duration of therapy. Progression-free survival was the primary endpoint; secondary endpoints included rates of complete or partial response, overall survival, safety, and toxicity. To date, 22 patients (95% female, 34 to 69 years) have been enrolled. All patients were evaluated for safety, estrogen receptor (ER) status, and progesterone receptor (PR) status; 16 patients received ≥2 cycles and were evaluated for efficacy. All patients were HER2-negative;
Annals of Oncology

Volume 19 | Supplement 8 | September 2008
doi:10.1093/annonc/mdn504 | viii

154P
SYNERGY OF NAB-PACLITAXEL AND BEVACIZUMAB ERADICATES LARGE ORTHOTOPIC BREAST TUMORS AND LYMPHATIC AND PULMONARY METASTASIS
S. Ray1, L. Volle2, C.M. Bivens3, V. Tries2, N. Desai5
1School of Medicine, Southern Illinois University, Springfield/UNITED STATES OF AMERICA, 2Rd, Abraxis BioScience, LLC, Marina del Rey/UNITED STATES OF AMERICA, 3Rd, Abraxis BioScience, LLC, Los Angeles/UNITED STATES OF AMERICA

Background: Nab-paclitaxel (Abraxane®, nab-pac) is an albumin-bound 130-nm particle form of paclitaxel that demonstrated greater efficacy and was well tolerated compared to the standard particle form of paclitaxel (Taxol®) and docetaxel (Taxotere®). We have previously shown that reactionary angiogenesis induced by chemotherapy correlated with increased VEGF production in tumors, and the combination of nab-paclitaxel and anti-VEGF-A antibody (bevacizumab, bev) has superior efficacy against both primary tumors and metastasis than monotherapies in medium-sized MDA-MB-231 tumors (~230 mm³) (Fan et al, AACR 2007, #2201). Herein, we studied the combination of nab-pac and bev on the growth and metastasis of large-sized (450-600 mm³) breast tumors.

Material and methods: Luciferase-tagged MDA-MB-231-Luc human breast carcinoma cells were implanted into mammary fat pads of nu/nu mice and allowed to reach an size of 450-600 mm³, before treatment with nab-pac at 10 or 30 mg/kg every 3 weeks (q3w). Pts with ECOG PS 2 or history of febrile neutropenia were excluded.

Methods:
The RiTa trial is a prospective multicentre phase I dose finding study. The determined dose for the phase II study will be 70 mg/m² bendamustine and 90 mg/m² paclitaxel. Effective regimen in patients with metastatic breast cancer. The determined dose for the phase II study will be 70 mg/m² bendamustine and 90 mg/m² paclitaxel occurred during the 1st cycle. Over all cycles the following severe haematological toxicities (grade 3 and 4) were documented: neutropenia 5 pts (1 pt dose-level 1, 2 pts dose-level 3, 1 pt dose-level 4, 1 pt dose-level 5), anemia 1 pt in dose-level 2. Relevant grade 3 and 4 non-haematological toxicities over all cycles were fatigue 2 pts (1 pt in dose-level 1 and 2), dyspnoea 1 pt in dose-level 5, infection 4 pts (1 pt in dose-level 3 and 3 pts in dose-level 5) and bone pain 1 pt in dose-level 2. Five serious adverse events (2 fatigue, 1 anemia, 1 allergic reaction, 1 dehydration), but no therapy related death occurred. Five of the 18 pts showed a complete or partial remission, 6 pts stable disease and 5 progressed during treatment. The median progression free survival was 8.5 months.

Conclusion: The treatment with weekly bendamustine and paclitaxel is a feasible and effective regimen in patients with metastatic breast cancer. The determined dose for the phase II study will be 70 mg/m² bendamustine and 90 mg/m² paclitaxel.
ERIBULIN MESYLATE (ET7389) IN PATIENTS WITH LOCALLY ADVANCED OR METASTATIC BREAST CANCER PREVIOUSLY TREATED WITH AN ANTHRACYLINE AND A TAXANE: PHASE II NEUROPATHY DATA


1Oncology Department, Vall d’Hebron Hospital, Barcelona/SPAIN, 2N/a, Centre d’Estudis Clinics de Barcelona, Spain/SPAIN, 3Oncology, Vall d’Hebron Hospital, Barcelona/SPAIN, 4N/a, Leeds Institute of Molecular Medicine, Leeds/UNITED KINGDOM, 5Division of Hematology/oncology, Weill Cornell Medical College, New York/UNITED STATES OF AMERICA, 6N/a, Baylor-Charles A. Sammons Cancer Center, Texas Oncology PA and US Oncology, Dallas and Houston/UNITED STATES OF AMERICA, 7N/a, El Paso Cancer Center, Texas Oncology PA and US oncology, Houston/UNITED STATES OF AMERICA, 8N/a, Eliai Medical Research Inc, Ridgefield Park/UNITED STATES OF AMERICA, 9N/a, Eliai Ltd, London/UNITED KINGDOM, 10N/a, Comprehensive Cancer Centers of Nevada and US Oncology, Las Vegas and Houston/UNITED STATES OF AMERICA

Purpose: To summarise neuropathy data for eribulin mesylate (ET7389), a non-taxane microtubule dynamics inhibitor with a novel mechanism of action, from two Phase II studies in patients (pts) with extensively pretreated locally advanced or metastatic breast cancer.

Methods: Two single-arm, open-label studies recruited pts with measurable disease. EOCG performance status 0–2, neuropathy Grade ≤2, prior anthracycline and taxane treatment, and progression on or within 6 months of their last chemotherapy (CT). Eribulin mesylate (1.4 mg/m²) was administered as a ≤5 min intravenous infusion on Days 1 and 8 of a 21-day cycle or on Days 1, 8 and 15 of a 28-day cycle. The primary efficacy endpoint was objective response rate (ORR; RECIST) assessed by independent review. Adverse event (AE) rates were graded according to NCI CTC v3.0. Neuropathy AE rates were evaluated using two approaches: investigator classification of relatedness (both studies), and pre-trial classification of neuropathy severity and evaluation of worsening (one study).

Results: Patients in the two studies had received a median of four prior CT regimens. Eribulin was administered to 394 pts (safety population) for a median of four cycles. In the study for which pre-trial neuropathy severity was classified, 235 of 291 eribulin-treated pts (81%) had no pre-existing neuropathy and 56 pts (19%) had pre-existing neuropathy. In these two groups, only 23% developed neuropathy and 21% stopped eribulin therapy. Eribulin was associated with a manageable level of neuropathy, and pre-existing neuropathy usually did not worsen with eribulin treatment.

Conclusions: Eribulin was associated with a manageable level of neuropathy, and pre-existing neuropathy usually did not worsen with eribulin treatment.

ELIXIR: A LARGE, PROSPECTIVE COHORT STUDY EVALUATING ROUTINE CLINICAL USE OF CAPECITABINE (CAP) IN ADVANCED BREAST CANCER (ABC) IN FRANCE

L.L. Ray-Coquard1, B. Aselefe2, M. Debled3, P. Dalvoust4, H. Homokos5, N. Duffaut6, C. Flament7, X. Pivot8
1Medical Oncology, Centre Léon Bérard, Lyon/FRANCE, 2Statistic Department, Institut Curie, Paris/FRANCE, 3Medical Oncology, Institut Bergonie, Bordeaux/FRANCE, 4Medical Oncology, Hôpital Ambroise Paré, Marseille/FRANCE, 5Gînno Onco-hematologie, Roche, Neutally sur Seine/FRANCE, 6Biometry, Roche, Neutally sur Seine/FRANCE, 7Medical Oncology, Centre Hospitalier Universitaire, Besançon/FRANCE

Purpose: This French pharmaco-epidemiological study aims to assess use, efficacy, tolerability (reported by patients [pts] and physicians) and compliance with Cap in routine oncology practice, to analyse characteristics of pts treated with Cap and to identify the principal prognostic factors for disease progression.

Methods: Physicians were recruited using a step-by-step method to ensure proportional representation from all types of medical practice (comprehensive cancer centres, university hospitals, general hospitals, private clinics) and avoid selection bias. Data on pts’ baseline characteristics, Cap treatment dose/schedule, efficacy, tolerability and compliance were collected by physicians. Tolerability and compliance data were also collected from pts.

Results: From Dec 05 to Nov 07, 83 participating physicians enrolled 616 analysable pts on Cap treatment. Cap was administered as follows: 60mg/m², S-1 40mg/m² BID; Level 2: DOC 70mg/m², S-1 40mg/m² BID, respectively. Twelve pts (median age 59, range: 37–66) were enrolled. The only DLT was defined as any of the following events occurring during cycle 1: grade 4 neutropenia for 4 days or more, grade ≥3 febrile neutropenia (ANC≤1,000, 38°C), grade ≥3 non-haematologic toxicities other than nausea, vomiting, anorexia, or fatigue.

Cap prescription: most pts received Cap as monotherapy (72%) and in the first-line setting (42%). The most common chemotherapy partner was vinorelbine (n=60). 56 pts received Cap + trastuzumab. The mean daily dose of Cap was 1920 mg/m² (range 317–2791). Self-administered questionnaires were received from 81% of pts.

Conclusions: In this large, prospective cohort study, Cap was given most commonly as first-line therapy for ABC (42% of pts). Pts receiving Cap in this setting appeared to have less aggressive disease (more bone-only metastasis, fewer metastatic sites). Efficacy, tolerability and compliance data will be available early in 2009.

A PHASE I STUDY OF S-1, A NOVEL ORAL FLUOROPYRIMIDINE, COMBINED WITH DOXETAXEL FOR ADVANCED OR RECURRENT BREAST CANCER

M. Takahashi1, M. Hosoda1, H. Takahashi1, K. Watamine1, K. Taguchi2, M. Tamura1, Y. Hata1, S. Tokoi1
1First Department of Surgery, Hokkaido University Hospital, Sapporo/JAPAN, 2Department of Surgery, Sapporo Social Insurance General Hospital, Sapporo/JAPAN

Background: S-1 is a novel oral fluoropyrimidine consisting of tegafur, gimeracil, andoterax. S-1 monotherapy demonstrated 20% overall response rate for refractory metastatic breast cancer (MBC) patients after anthracyclin and taxan therapy. Doxetaxel (DOC) is one of the most active chemotherapies for (MBC), combination of DOC plus S-1 is a promising treatment option for MBC. We conducted a Phase I study to establish the dose limiting toxicity (DLT) and maximal tolerated dose (MTD) of S-1 plus DOC.

Patients and methods: Eligible patients (pts) had advanced or recurrent breast cancer, age 20 to 70 years old, with ECOG PS 0–1. DOC was administered on Day 1 and S-1 was administered Day 1 to 14 followed by a 7 day rest. Cycles were repeated every 3 weeks until disease progression, unacceptable toxicity, or withdraw of consent. Planned dose escalation was Level 1: DOC 60mg/m², S-1 32.5mg/m² BID per day; Level 2: DOC 70mg/m², S-1 40mg/m² BID, respectively. DLT was defined as any of the following events occurring during cycle 1: grade 4 neutropenia for 4 days or more, grade ≥3 febrile neutropenia (ANC<1,000, 38° C), grade ≥3 other non-haematologic toxicities other than nausea, vomiting, anorexia, or fatigue.

Results: Twelve pts (median age 59, range: 37–66) were enrolled. The only DLT observed was grade 4 neutropenia for 4 days or more, occurring in 1 of 6 pts at Level 2 and 2 of 3 at Level 3. Efficacy data will be present at the meeting.

Conclusions: Based on our findings we recommend dose of S-1 40mg/m² BID Day 1–14 and DOC 60 mg/m², Day 1 every 3 weeks for phase II studies in advanced or recurrent breast cancer.
Fulvestrant as first-line treatment for advanced breast cancer in postmenopausal women after progression on prior adjuvant therapy with third-generation aromatase inhibitors: A phase II trial

P. Palumbo1, A. Bernardò2, M.R. Strada3, C. Tenaghi, G. Poggi4, M. Frascaroli5, A. Amatu2, G. Bernardò4
1Oncologia Medica 2, Fondazione S. Maugeri, Pavia/ITALY, 2Medical Oncology II, Fondazione S. Maugeri, Pavia/ITALY, 3Rehabilitative Oncology, Fondazione S. Maugeri, Pavia/ITALY

The aim of this phase II study was to evaluate the safety and efficacy of fulvestrant in postmenopausal hormone-sensitive women with advanced breast cancer (ABC) progressing after adjuvant treatment with AI. The primary end point was time to progression (TTP) and the secondary end point was the clinical benefit (CB) rate. Fifty-two consecutive patients were enrolled: median age of 67 years (range 35-78); ECOG performance status 0-1 in 90%. Anthracycline-based adjuvant chemotherapy had been given in 45% of patients, with sequential hormonal therapy, and 92% of patients had received radiotherapy. The primary end point consisted of anastrozole in 51% of patients, letrozole in 34%, and exemestane switching from tamoxifen in 15% of patients (adjuvant setting only). Disease-free interval was 5 years in 45%. Dominant metastatic sites were viscera (liver/lung in 72% of cases) and bone (20% of cases). Fulvestrant was administered at registered dose of 250 mg via intramuscular injection every 28 days, until disease progression or other reason for discontinuation. Treatment allowed good patient compliance, with mild-moderate adverse events. The median TTP was 6 months (6-22). Our results confirm that fulvestrant is a well-tolerated and effective strategy as first-line treatment in hormone-sensitive postmenopausal women who had progressed after prior adjuvant treatment with third-generation IA. The good treatment compliance and the possibility to delay the less-tolerated chemotherapy option could positively affect patient’s quality of life.

Oral vinorelbine in metastatic breast cancer – the Vienna experience

R. Bartl1, U. Puschnig1, C. Wenzel1, S. Camperdenrieder1, G. Aitorja1, M. Gnait1, M. Holderegger2, A. Mittnacht2, C. Zeieliiski2, G.G. Slager2
1First Department of Medicine, Medical University of Vienna, Vienna/AUSTRIA, 2Department of Surgery, Medical University of Vienna, Vienna/AUSTRIA, 3Department of Pathology, Medical University of Vienna, Vienna/AUSTRIA, 4Department of Radiotherapy, Medical University of Vienna, Vienna/AUSTRIA, 5Dept. Medicine 1, University Hospital and Cancer Centre, Vienna/AUSTRIA, 6Medicine and Cancer Center, Medical University of Vienna, Vienna/AUSTRIA

Background: Metastatic breast carcinoma is an incurable disease. Treatment aim remains palliative – to control symptoms and, were possible, prolong survival, while maintaining quality of life. Therefore, there is an important role for oral chemotherapy, as it was found to receive higher patient acceptance. Here, we report the experience with oral vinorelbine (OV) in anthracyclin-resistant metastatic breast cancer.

Patients and methods: A total of 100 consecutive patients were included as eligible for OV and followed prospectively. Her2-positive subjects received a combination of OV and trastuzumab. As earlier described, OV was administered at a dose of 60 mg/m2 on day 1 and 8, q=21, without dose escalation. Trastuzumab was given every three weeks at a dose of 4 mg/kg. A total of 42 metastatic breast cancer patients treated with first line hormonal therapy were enrolled in this study. Pretreatment body weight, height and BMI were measured. Serum leptin and estradiol levels were measured. Estrogen, progesterone and c-erb-B2 receptors status were evaluated in analyses. Univariate and multivariate Cox regression analyses, and Kaplan Meier survival curves subjected to log rank testing were utilized for the survival analyses. Forward likelihood ratio was used for the multivariate selection process. A P value < 0.05 was considered to be significant.

Results: Median age was 51 years (range 28 – 75). Median body weight, height and BMI were found to be 70.5 kg (range 46-115), 156 cm (range 137-167), 29.2 (range 18-45), respectively. Median leptin level was 1970 pg/ml (3990-1980) and estradiol level 319 pg/ml (252 – 184).19 patients were found to be obese (BMI ≥ 30). Factors associated with overall survival in the univariate analysis were grade 3 or 4 intensity. In patients on OV and trastuzumab, consistently superior TTP and response rate were observed.

Conclusions: OV appears to be feasible and safe at the dose and schedule chosen. Of note is the importance and good tolerability in elderly patients. Earlier reported, the combination of OV and trastuzumab offers a highly active regimen in Her2-positive disease. Similar to other treatment options, OV is most effective when used in the first-line setting. Updated results will be presented.

AN ANALYSIS OF THE PHARMACOKINETIC (PK) PROFILE OF FULVESTRANT 500 MG VS 250 MG: DATA FROM THE NEWEST STUDY

B. Backe1, I. Kuter2, R. Hegg3, F. Saquaro4, P. McCormack5
1Tata Memorial Hospital, Mumbai/INDIA, 2Massachusetts General Hospital, Boston/UNITED STATES OF AMERICA, 3School of Medicine, University of Sao Paulo & Pernia Byington Hospital, Sao Paulo/BRAZIL, 4AstraZeneca Pharmaceuticals, Macclesfield/UNITED KINGDOM

Background: NEWEST (Neoadjuvant Endocrine therapy for Women with Estrogen-Sensitive Tumours) is a randomized, Phase II study comparing fulvestrant approved dose (AD: 250 mg/month) with a high-dose regime (HD: 500 mg/month plus 500 mg on Day 14 of Month 1) as neoadjuvant therapy for postmenopausal women with newly diagnosed, oestrogen receptor (ER)-positive, locally advanced breast cancer. In the primary analysis, fulvestrant HD resulted in a statistically significant greater reduction in Ki67 labelling index (LI) and greater ER and progesterone receptor (PgR) downregulation compared with AD. Here we report PK data from NEWEST.

Methods: Core biopsies were taken at baseline, Wk 4 and at surgery (Wk 16), and assessed for changes in Ki67 LI, ER and PgR expression (ER and PgR Intensity Score analysed using ChromaVision™ Automated Cellular Imaging System). Blood samples for PK analysis were taken on Days 0, 28, 56, 84, and 112. An additional sample was taken between Days 6-10 (both groups) and Days 20-24 (HD only). HPLC-MS and liquid-liquid extraction were used to determine fulvestrant plasma levels. Plasma samples were analysed using NONMEM and Bayesian PK parameter estimates were used to determine Cmax and AUC0-28 days at Wks 4 and 16. Correlations between fulvestrant plasma levels, magnitude of biomarker (Ki67 LI, ER, and PgR) downregulation and clinical activity were assessed.

Results: A total of 208 women were included in the PK analyses. Fulvestrant plasma levels and exposure were greater for fulvestrant HD than AD at Wks 4 and 16 (Wk 4: Cmax, HD 24.5 ± 6.9 vs AD 8.8 ± 1.7 ng/mL; AUC0-28 days, HD 12804 ± 3550 vs AD 4035 ± 840 ng.h/mL). Increased monthly fulvestrant exposure correlated with increased Ki67 LL, ER and PgR downregulation. Detailed modelling of the endpoints suggested a non-linear decrease in both Ki67 and PgR to a plateau of approximately 20-30% of baseline values. ER levels were downregulated to approximately 50% of pre-treatment values. Conclusions: Increased fulvestrant exposure correlates with increased downregulation of Ki67 LL, ER and PgR. The relationship between drug levels and clinical response will also be presented. Fulvestrant HD is currently being investigated in the metastatic disease setting.
inhibition of this combination. Supported by ARCO foundation.

**Methods:**
We reviewed the records of 950 patients with breast cancer treated at our institutions during 1997 to 2003 and found that 38 (4%) developed CNS metastases. In these 38 patients, we analyzed the clinical course, pathology, and primary tumor immunohistochemistry profile of hormone receptors, HER-2, p53, and microvessel density by the Chalkey count technique using the anti-CD105 antibody E-9.

**Results:** The results of this study showed that the difference in clinical response of breast cancer patients caused by variation of MDR-1 gene exon 26 on 3435 position, which can make difference in clinical response without affecting the positive or negative Her-2 expression. Patient with mutation type pattern (genotype T/T) have clinical response, while patients who do not show clinical response have wild type pattern.

**Conclusion:**
Our result showed that breast cancer patients with positive Her-2 expression are not always responsive to anthracycline application, meaning that only patients with mutation type pattern (genotype T/T) of MDR-1 gene exon 26 on 3435 position have clinical response, while patients who do not show clinical response have wild type pattern.

**Purpose:**
The purpose of this study was to reveal those mechanisms, which in the future could be used as the basis of anthracycline application in breast cancer patients.

**Background:**
The translational research in nineteen patients diagnosed between January until December 2005 with locally advanced breast cancer treated by preoperative anthracycline chemotherapy to evaluate its predictive outcome was performed. All samples were analyzed by immunohistochemistry, PCR, and sequencing methodology of the MDR1 target gene.

**Results:**
The results of this study showed that the difference in clinical response of breast cancer patients caused by variation of MDR-1 gene exon 26 on 3435 position, which can make difference in clinical response without affecting the positive or negative Her-2 expression. Patient with mutation type pattern (genotype T/T) have clinical response, while patients who do not show clinical response have wild type pattern.

**Conclusion:**
Our result showed that breast cancer patients with positive Her-2 expression are not always responsive to anthracycline application, meaning that only patients with mutation type pattern (genotype T/T) of MDR-1 gene exon 26 on 3435 position have clinical response, while patients who do not show clinical response have wild type pattern.

**Purpose:**
The purpose of this study was to reveal those mechanisms, which in the future could be used as the basis of anthracycline application in breast cancer patients.

**Background:**
The translational research in nineteen patients diagnosed between January until December 2005 with locally advanced breast cancer treated by preoperative anthracycline chemotherapy to evaluate its predictive outcome was performed. All samples were analyzed by immunohistochemistry, PCR, and sequencing methodology of the MDR1 target gene.

**Results:**
The results of this study showed that the difference in clinical response of breast cancer patients caused by variation of MDR-1 gene exon 26 on 3435 position, which can make difference in clinical response without affecting the positive or negative Her-2 expression. Patient with mutation type pattern (genotype T/T) have clinical response, while patients who do not show clinical response have wild type pattern.

**Conclusion:**
Our result showed that breast cancer patients with positive Her-2 expression are not always responsive to anthracycline application, meaning that only patients with mutation type pattern (genotype T/T) of MDR-1 gene exon 26 on 3435 position have clinical response, while patients who do not show clinical response have wild type pattern.
**167** PHASE II TRIAL OF PACLITAXEL AND URACIL-TEGAFUR IN METASTATIC BREAST CANCER. TEGATAK TRIAL

C.B. Wiltzius1, L. Chaillou1, T. Nguyen1, A. Dulhunty1, U. Stein2, M. O'Connor3, T. Maurin1, C. Borg1, F. Auduy1, X. Plot1

1Oncologie Medicale, University Hospital of Besançon, Besançon/France, 2Oncologie Medicate, Hospital of Dole, Dole/France, 3Oncologie Medicale, Merck Ljipa Sainte, Lyon/France

**Introduction:** This Phase II trial investigated the combination paclitaxel (P) and uracil-tegafur (UFT) in patients (pts) with metastatic breast cancer (MBC).

**Methods:** Eligibility criteria included HER-2 negative MBC, an ECOG performance status of 0-2, exposure to >3 prior chemotherapy regimens at the metastatic setting, and a previous exposure to an anthracycline containing regimen. Additional criteria included measurable disease, neuropathy < Grade 1, no uncontrolled brain metastases and adequate organ function. Each 35-day cycle consisted of P at 80 mg/m² IV on days 1, 8, 15, 21 and 28, UFT at 300 mg/m² and folinic acid at 15 mg PO TID from days 1 to 28. Treatment was continued until disease progression, unacceptable toxicity, intolerance or withdrawal of consent. Responses were evaluated by RECIST criteria every 2 cycles. The primary endpoint was overall response rate (ORR). Secondary endpoints included progression-free survival (PFS), overall survival (OS), duration of response (DR) and safety.

**Results:** Between 2003 and 2007, 31 patients were enrolled. Median age was 66 yrs (range 44-78), 7% of pts was triple negative and 81% of pts had visceral disease. A total of 18 pts had received adjuvant chemotherapy, 97% and 3% had 1 and 2 lines of chemotherapy for metastatic diseases, respectively and 74% had a previous doxetaxel containing treatment. One patient did not receive treatment and was subsequently excluded from analysis. Median of 4 and 3 cycles of P and UFT were administered with a relative dose intensity of 85.3% and 94.3 %, respectively. Among 30 treated pts, 12 (40%) (IC95% 22.5-57.5) had confirmed ORR. Stable and progressive disease were reported in 43% and 17%, respectively. Median DR was 8.3 month (IC95% 4.9-11.7), median PFS was 14.6 months and median OS was 23 months. Thirteen pts (43%) experienced grade 3/4 adverse event: neuropathy (4), diarrhea (2), and abdominal liver function test (1). One death occurred related to the study drugs (febrile neutropenia). Chemotherapy was discontinued due to toxicity in 9 of pts, P was stopped in 41% pts and UFT in 51%.

**Conclusion:** ORR is encouraging and warranted further studies with other doses and schedules.

---

**168** BEVACIZUMAB, CARBOPLATIN AND VINORELBINE FOR METASTATIC BREAST CANCER

K.T. Papazisis1, T. Vassiliadis2, L. Kontivinis, C. Andreadis, D. Mouratidou

3rd Department of Medical Oncology, Thessaloniki Greece

**Introduction:** Monoclonal anti-VEGF antibody bevacizumab in combination with paclitaxel has recently been approved as first-line treatment for metastatic breast cancer (MBC). However, there are many breast cancer patients who are not candidates for the combination, either due to intolerance of paclitaxel or due to paclitaxel-resistant disease. Moreover, there have been reports of bevacizumab activity beyond the first line of treatment. We use a combination of bevacizumab, carboplatin and vinorelbine (ACV) in metastatic breast cancer patients that are resistant to taxanes (DFS less than 6 months) for 6 months. Treatment was well tolerated; however, in three patients a dose-adjustment was required, mainly due to hematological toxicity. There were six patients who received 6 cycles of bevacizumab, but only one episode of febrile neutropenia that needed iv antibiotics. G-CSF was administered in ten patients and erythropoetin in six. One patient, receiving ACV as third line treatment had an impressive partial response in lung and complete response in liver metastases; however she developed an asymptomatic thrombus of the inferior vena cava. Treatment was discontinued and she received LMWH, hormonal treatment andibandronate. She is still progression-free and asymptomatic. There were no treatment-related deaths.

**Conclusions:** Bevacizumab, carboplatin and vinorelbine is an effective combination for the treatment of metastatic breast cancer, even beyond the first line. The main toxicity is hematological; it is, however, easily managed.

---

**169** FRENCH EXPERIENCE OF PATIENTS’ MANAGEMENT WHEN RECEIVING VINORELBINE ORAL CHEMOTHERAPY (NVBO) FOR A METASTATIC BREAST CANCER: FIRST RESULTS OF A PROSPECTIVE OBSERVATIONAL SURVEY ON PRACTICES

J.P. Lotz1, F. Hussein2, M. Finck3, M. Rotarski4, L. Basti4, A. Riviere4, A. Yousset5, S. Nahon6, F. Bvilk 7

1Medical Oncology, Hospital Tenon, Paris/France, 2Medical Oncology, General Hospital, COLMAR/France, 3Medical Oncology, Private Oncology Institute, Cruso/France, 4Medical Oncology, Oncology Center, Bayonne/France, 5Medical Oncology, Frederic Joliot Center, Rouen/France, 6Medical Oncology, Francois Baclesse Center, Caen/France, 7Medical Oncology, Jean Godinot Center, Reims/France, 8Medical Oncology, Oncology Center, Aix-en-Provence/France, 9Medical Oncology, Hospital Center, Aix-en-Provence/France, 10Medical Oncology, Institute of Research Pierre Fabre, Boulogne-Billancourt/France

**Background:** An observatory on practices has been implemented in France with the aim of investigating the correlation between patient (pt) profile and the use of oral chemotherapy (OCT), NVBO.

**Methods and Materials:** Three questionnaires were used: a “Physician” questionnaire (medical practice conditions, physician profile, prescription habits, role of OCT), a “Patient” questionnaire (completed by the physician describing the pt disease history and characteristics, general condition, prescription selection factors, monitoring and compliance), and a Patient Preference self-questionnaire (partly based on the EORTC QLQ-BR23). 350 pts were planned, 5-15 patients per physician.

**Results:** An interim analysis was performed on the first 200 pts enrolled since 02/2006 in 37 centres: private centers (45%), public hospitals (44%) and cancer institutes (11%). Pts had previously received CT [82.5% - intravenous(iv) CT in 77% (including iv + OCT in 8 %)] and hormonal therapy (72.5%). 31% of pts had already received OCT (41.9% with a slowly progressing tumour). The breast tumours were mainly considered as having limited aggressiveness (82.7%) with no visceral metastasis (37.8%) or with slowly progressing visceral metastasis (DFI > 24-36 months) for 44.9% of them. Physician’s major parameters of OCT choice were: patient-related factors (QOL; 97.3% and pt preference 83.7%); treatment-related factors (efficacy 94.6%, maintenance or consolidation 37.8%); venous administration concerns (54%) and economic reasons (58.3%). NVBO was prescribed as monotherapy in 56% and combined with other agents in 44% (in 50.6% and oral in 64.4%). According to physicians, pts preference for OCT was related to: reduced hospital stays (78.4%), improved QOL (freedom 63.9% and convenience 78.6%). Treatment compliance, according to patient declarations, was 91.3%.

**Conclusions:** NVBO brings added value in terms of pt acceptance, allowing optimal compliance to treatment schedule. Final data will be presented at the congress.

---

**170** BENEFIT OF NEOADJUVANT DOCETAXEL IN TREATMENT OF BREAST CANCER

S. Elmesidy1, H. Atteya1, A. Elkashif1, W. Hammam2

1Clinical Oncology, Faculty of Medicine - Cairo University, Cairo/Egypt, 2Clinical Oncology, Faculty of Medicine - Cairo University, Cairo/Egypt

**Aim:** To prospectively compare neoadjuvant docetaxel with anthracycline-based chemotherapy as regards efficacy and toxicity in patients with locally advanced breast cancer who initially failed to respond on other anthracycline based combination.

**Patients and methods:** Patients with locally advanced breast cancer were randomized to receive either 3 cycles of FAC (arm A) or 3 cycles of TAC (arm B). Clinical and radiological tumor responses were assessed after 3 cycles. Responders continued on the same regimen for another 3 cycles before surgery. Non-responders in arm A received 3 cycles of docetaxel single agent at a dose of 100mg/m². Non-responders in arm B were treated by surgery or radiotherapy followed by second line chemotherapy.

**Results:** Thirty female patients were enrolled in each arm. None of the patients achieved CR in both arms. PR was documented in 100% of the patients in arm A, whereas only 17 patients (56.7%) achieved PR in arm B. The rest of the patients in arm B had stable disease in 9 patients(30%) and progressive disease in 3 patients (10 %). After 6 cycles of chemotherapy CR was achieved in 3 patients (10%) and 8 patients (26.7%) respectively in arm A and B. In arm A 22 patients (73.3%) had PR, 4 patients (13.4%) had SD and one patient (3.3%) had PD. The remaining 22 patients (73.3%) in arm B continued to have PR. Assessment of the conservation rate showed that...
RESPONSE EVALUATION TO INDUCTION CHEMOTHERAPY IN PATIENTS WITH INFLAMMATORY BREAST CARCINOMA

D. Kalameka1, Z. Tomasevic2, S. Mivojevic3, N. Andjelic-Dekic1, S. Jelic1
1Daily Chemotherapy Hospital, Institute for Oncology and Radiology, Belgrade/ SERBIA AND MONTENEGRO, 2Medical Oncology, Institute for Oncology and Radiology of Serbia, Belgrade/SERBIA AND MONTENEGRO, 3Daily Chemotherapy Hospital, Institute for Oncology and Radiology, Beograd/ SERBIA AND MONTENEGRO

Background: Response evaluation in patients with inflammatory breast carcinoma (IBC) still represents challenge, because standard criteria especially for partial remission and disease stabilization definition, usually cannot be applied. The aim of this retrospective analysis is to evaluate responses to induction chemotherapy in IBC.

Patients and methods: Among 2154 breast carcinoma (BC) pts. registered during one year at the Institute for Oncology and Radiology of Serbia (IORS), 178 patients (8,2%) had clinical diagnose of IBC. Results: Data was available for 82 IBC pts. Median age was 59 range (42-81); stage III 76%, stage IV (24%); Lymphangiosis confirmed in 56 pts; underlying BC confirmed in 95 pts. and 4.8% pts. had only skin lymphangiosis, without underlying BC Stierer receptor status was measured in 93% (6%). At least one receptor - 39% (30 pts) HER2 status (IHH, Dhal) assessed in 52 pts (83%); HER2 3+ 33%; triple negative 11% Induction chemotherapy: FAC in 65 pts (79%) CMF in 18 pts (26%) 6 pts treated with tamoxifen only, due to poor PS Trastuzumab was not given. Responses were evaluated after 4-6 chemotherapy cycles. Clinical and mammography CR was defined as complete disappearance of previously palpable breast tumor; no clinical and mammography signs of cancer mastitis; no enlarged regional lymph nodes, and disappearance of all metastatic sites, if any. CR is achieved in 4 (8,4%) all treated with FAC, for stage III One CR achieved in HER 2 + IBC.PD as best response is recorded in 24,3% of pts. Responses that could be only defined as disease control, defined as no CR, no PD, without certain characteristics for either PR or SD, is achieved in 75, 9% of pts and 17% could not be interpreted.

Conclusion: Incidence of IBC seems to be higher than reported in the literature (8,2% vs 1-4%). Clinically and by mammography, CR was achieved in 4,8% patients. However, responses other that CR and PD could not be accurately defined because inconsistency of response description. Therefore, there is a clear need for determination of specific response criteria for IBC.

PROGNOSTIC FACTORS IN PATIENTS WITH BREAST CANCER AND MALIGNANT PLEURAL EFFUSION

K. van Galen1, H. Visser2, T. van de Ploeg3, C. Smorenburg2
1Oncology, Medical Centre Alkmaar, Amsterdam/NETHERLANDS, 2Oncology, Medical Centre Alkmaar, Alkmaar/NETHERLANDS

Background: malignant pleural effusion (MPE) is frequently seen in patients with breast cancer and has been associated with poor prognosis in studies performed more than 2 decades ago. As recent advances in breast cancer treatment have improved survival, we investigated current survival and prognostic factors in these patients.

Patients and methods: we analyzed data from all patients (n = 49) registered during 2000-2006 with breast cancer and cytological confirmed MPE at Medical Centre Alkmaar Hospital. Results: Median age at the time of diagnosis of MPE was 65 years (range 32-88 years). Most effusions were uni- and ipsilateral to the affected breast (61% ( 47 pts..) ; both effusions were present in 60% (18pts.). All patients had histologically confirmed breast cancer. The favourable toxicity profile of this oral treatment makes of oral MTX and CTX. Data on clinical efficacy and toxicity are presented.

Conclusion: The incidence of IBC in our clinic is higher than reported in the literature. Clinical and mammography CR was achieved in 4.8% patients. Responses other that CR, PD could not be accurately defined because inconsistency of response description. Therefore, there is a clear need for determination of specific response criteria for IBC.

N/T QUOTIENT: A CLINICAL PROGNOSTICAL FACTOR RELATED WITH EXPRESSION OF BIOLOGICAL PREDICTIVE FACTORS

Clinical Oncology Department, University Hospital Reina Sofia of Cordoba, Cordoba/SPAIN

Introduction: The N/T quotient is the relationship between the number of positive auxiliary lymph nodes (N) and the size of the primary tumour (T). There are studies that related this quotient to time to progression in patients with metastatic breast cancer. Furthermore, breast cancer can be classified according to the immunohistochemical study in different biological profiles, each with a different prognosis. Objectives: Analyze the quotient N/T in the different biological profiles according to immunohistochemical study. Method: We analyzed a series of 230 women with breast cancer and a known N/T quotient between ≤ 2 and > 2. The patients were classified retrospectively, according to age of diagnosis, histological type, differentiation grade, stage, hormonal receptors (ER and PR) and ESR2. The data were analyzed using contingency tables and chi-square distribution, according to the statistical program SPSS 12.0. RESULTS: The mean age at diagnosis was 56.7 years (26-85). The most common stage was Ib (42.7%). The most frequent histological type was infiltrating ductal carcinoma with moderate grade of differentiation (35.6%). We also analyze the grade the differentiation, estrogen expression, progesterone, Ki67, and Her-2 in patients with N/T quotient ≤ 2 or > 2. In the analysis the triple negative phenotype is more frequent in those women with N/T > 2 quotient (19%), p=0.0018.

Conclusion: Those patients with high N/T quotient (> 2) have more aggressive phenotype.

CARDIAC TOXICITY WITH TRASTUZUMAB IN METASTATIC BREAST CANCER-USE BEYOND ONE YEAR

V. Vyas, S.A. Awadi, J. Nemec, H. Khalid, M.C. Krishnan
Medical Oncology, Kuwait Cancer Control Centre, Kuwait/KUWAIT

Introduction: In patients with breast cancer the duration of treatment with adjuvant trastuzumab (Herceptin) is one year. In patients with metastatic breast cancer who continue to benefit from trastuzumab, the time frame to stop trastuzumab is not defined. The most common limiting factor is cardiac dysfunction. With this background the data sheet for metastatic breast cancer receiving trastuzumab for one year and beyond were studied at our centre.

Conclusion: No adverse events were experienced by the patients. The median follow-up time was 48 months (range 12-96) and all the patients continue to receive treatment. This study supports the use of trastuzumab beyond one year for patients with metastatic breast cancer.
scans were done at baseline for all the patients and followed every 3 months. Left ventricular ejection fraction (LVEF) decrease of >15% points or to <50% was used as a surrogate for clinical cardiac events.

Results: Forty six patients were identified receiving trastuzumab ranging from 12 months to 33 months. Baseline MUGA scan was showing essentially normal LVEF (mean 59%). Three patients (6.5%) stopped trastuzumab after a non-symptomatic significant fall of LVEF. Of which one patient was restarted with trastuzumab after 3 months when she recovered her LVEF. Total duration of trastuzumab received was from 12 months to 33 months (mean 15.5 months).

Conclusion: The risk of cardiac toxicity was observed matching with international experience. In one of the patients the decline in LVEF was reversible and we could restart trastuzumab treatment safely. With regular follow up by MUGA scans trastuzumab can be given safely for longer periods.

Annals of Oncology

CLINICAL EXPERIENCE WITH FULVESTRANT, PURE OESTROGEN RECEPTOR (RE) ANTAGONIST WITH NO AGONIST EFFECTS, IN PRE-TREATED ADVANCED BREAST CANCER PATIENTS

A. Sánchez-Muñoz1, I. Blancas2, E. González2, A. Martínez2, A. Jaen-Morago2, P. González-Ruivo1

1Oncology, Hospital Universitario Médico Quirúrgico Ciudad de Jaén, Jaen/SPAIN, 2Oncology, Hospital Clínico de Granada, Granada/SPAIN, 3Oncology, Hospital Virgen de las Nieves, Granada/SPAIN, 4Oncology, Hospital Severo Ochoa, Leganés/SPAIN, 5Oncology, Hospital Reina Sofia, Córdoba/SPAIN, 6Hospital Carlos Haya, Oncology, Málaga/SPAIN, 7Oncology, Hospital de Jaén, Jaén/SPAIN

Objective: To determine Fulvestrant (F) Clinical Benefit (CB) in pre-treated patients (pts) with hormone-receptor positive advanced breast cancer (ABC).

Methods: Eighty four ABC patients treated with F 250 mg i.m. monthly were evaluated. Histology: 76% ductal, 17% lobular, 7% others. Median age: 64 (42 - 79). Hormone Receptor status: ER + R+ 78 pts (69%), ER - R+ 19 pts (15%); ER - R- 4 pts (5%) and unknown: 3 pts (4%). Non visceral metastases 61 pts (73%) and visceral metastases: 23 pts (27%). Fifty percent of pts received ≥ 2 more prior therapies for advanced disease (chemo and/or endocrine therapies).

Results: The mean of F doses was 8 (2-22). 60 pts (71%) experienced CB with F: 5 pts CR (6%), 19 pts PR (22%) vs 36 pts (43%) SD ≥ 24 weeks. There was a non significant statistical trend to greater CB in first and second line treatments versus more than 2 (75% vs 67%), and in RE - R+ tumors vs RE + R-. RE vs RE - R+ ones (74% vs 68% vs 50%). The median time to progression (TTP) was 16.8 months in pts with CB vs 4.2 months in pts without CB (p<.0001). There were no serious adverse events only hot flashes in 8 pts (9%), gastrointestinal disturbances in 11 pts (13%), injection site pain in 3 pts (3%), arthralgia and weight gain in 1 pt.

Conclusion: Fulvestrant showed an important clinical activity even in heavily pre-treated ABC patients with a good toxicity profile. The right selection of patients in Fulvestrant showed an important clinical activity even in heavily pre-

Annals of Oncology

ADVANCED BREAST CANCER PATIENT POPULATION IS HETEROGENEOUS IN TERMS OF QUALITY OF LIFE (QOL) IMPAIRMENT

S.A. Kalyadina1, T.I. Ionova1, A.V. Klishitovich1, A.A. Novik2, G. Gorodokin2

1Unit of Qol Research In Cancer, Multinational Center of Quality of Life Research, St. Petersburg/ RUSSIAN FEDERATION, 2Department of Haematology and Cellular Therapy, Pirogov National Medical Surgical Center, Moscow/ RUSSIAN FEDERATION, 3Department of Qol Research, New Jersey Center for Quality of Life and Health Outcomes Research, New Jersey/UNITED STATES OF AMERICA

The major goals of treatment of advanced breast cancer patients are maintenance of quality of life (Qol) and palliation of cancer-related symptoms. We aimed to study Qol treatment response and symptom dynamics in advanced breast cancer patients receiving once-monthly i.m. injection of Faslodex (fulvestrant) 250 mg. 114 postmenopausal women with disease progression after prior antiestrogen therapy were enrolled in phase IV multicenter longitudinal study (the data collection will be finalized by September 2008). Qol was assessed using SF-36; symptoms – M.D. Anderson Symptom Inventory at base-line and at different time points within the year of treatment. The distribution of patients according to the grades of Qol impairment using normative data was provided. To evaluate Qol response the Integral Qol Index was calculated at base-line and in 3 months. Data on 62 women (mean age – 56.5; SD 9.5) were included in the preliminary analysis. Half of the patients experienced critical (22.5%) or severe (27.3%) Qol impairment. Moderate and mild Qol impairment was observed in 12.5% and 7.5% of patients, respectively: 4.2% of patients had no Qol impairment. All patients with critical and severe Qol impairment experienced fatigue: 90 % - pain, sleep disturbance, distress, and dyspnea. More than half of the patients reported significant (5 and higher on 10 scale) level of these symptoms. After 5 months of treatment Qol stabilization was shown in 58% of patients, Qol improvement – in 29% of patients, and Qol worsening – in 13% of patients. The majority of patients with fatigue, pain, and distress before treatment had either symptom reduction (42-49%) or symptom stabilization (29 - 37%). Sleep disturbance and dyspnea reduced in 38% and 37% of patients and stabilized in 35% and 37% of patients, respectively. Three preliminary data show that the use of the fulvestrant in the adjuvant settings for advanced breast cancer patients resulted in high Qol response rates, namely the majority of the patients experienced Qol improvement or Qol stabilization after 5 months of treatment. Symptom relief was observed in almost half of the patients. Evaluation of Qol response is a key issue for management of advanced cancer patients.

Taking into account that in advanced breast cancer (ABC) Qol is the major outcome, treatment strategy might be dependant on the degree of Qol impairment. We have assumed the following grades of Qol impairment as compared to a population norm (PN): mild (25-75% decrease from a PN), moderate (25-50% decrease), severe (50-75% decrease) and critical (>75% decrease). We aimed to study distribution of ABC patients according to the grades of Qol impairment. 250 women (mean age 56.1) were enrolled in the study. To compare with controls a gender- and age-adjusted sample from the population norm was used. SF-36 and M.D. Anderson Symptom Inventory (consists of 0-10 scale for thirteen symptoms) were used for patient-reported outcomes assessment. To distribute patients according to the grades of Qol impairment the Integral Qol Index was calculated for each patient on the basis of SF-36 scales. The majority of patients experienced critical (25.6%) or severe (16.8%) Qol impairment. Moderate and mild Qol impairment was observed in 13.6% and 11.2% of patients, respectively. 32.8% of patients had no Qol impairment. The value of Qol indices differed significantly depending on the grade of Qol impairment (P<0.01, Mann-Whitney test). The number of symptoms experienced by a patient simultaneously differed across the groups (P<0.001, Fisher’s exact test). In the group with critical Qol impairment the largest number of patients (28%) reported all 13 symptoms. On average, patients in the groups with critical and severe Qol impairment had 10 symptoms corresponding to terms of quality of life impairment. The majority of patients exhibiting critical or severe Qol impairment compared with a population norm. The number of symptoms experienced by the patients differed significantly depending on the group of Qol impairment. Grade of Qol impairment with the special emphasis to the groups with critical and severe Qol impairment is worthwhile to provide adequate management of advanced breast cancer.
COMBINATION OF PALONOSETRON AND BROMAZEPAM AS PRECAUTION AGAINST VOMITING CAUSED BY CHEMOTHERAPY IN PATIENTS WITH BREAST CANCER

V. Xourafas, P. Heras, A. Hatzopoulos, K. Kritikos
Internal Medicine, General Hospital, Nafplio/GREECE

Palonosetron (P), a selective competitor of the 5-HT3 receptor, is a highly effective drug against nausea and vomiting caused by chemotherapeutic cytotoxic factors that have highly emetic side effects. Its effectiveness though is decreased in patients who are treated with factors that only moderately cause vomiting. In this study, a combination of palonosetron (P) and bromazepam (B) was used as a precaution for patients with breast cancer (BC), treated with chemotherapy with moderate vomiting side effects. The scheme administered as follows: palonosetron 250 µg iv bolus 30 min before chemotherapy; bromazepam - tab 3 mg p.o.s. 60 cases out of 64 patients originally included in this study were studied. Results: The total degree of response was 93.4%. Complete or significant response was observed at 53.2% of the patients. As far as the safety and tolerance are concerned, the present study showed that all patients tolerated the treatment well and side effects; (8 patients displayed fatigue, 6 headache, 4 tachycardia, 2 constipation, and 2 fever) were mild and temporary.

Conclusion: The combination of P and B is highly effective at controlling vomiting caused from moderately vomit-producing cytotoxic chemotherapeutic factors that are given to patients with breast cancer.